James M. Frates
CIK: 0001235598
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct9.8K shares at avg. $32.27$315K - Sep 10, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct1K shares at avg. $33.23$35K - Aug 18, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct22.8K shares- - Mar 5, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct96K shares- - Mar 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct7.9K shares at avg. $14.52$115K - Feb 2, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct3.6K shares at avg. $14.65$52K - Jan 6, 2026AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct3.3K shares at avg. $11.11$37K - Sep 30, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct10.6K shares at avg. $14.65$155K - Jul 31, 2025SAGE
Sage Therapeutics, Inc.
Tender Offer(U)Direct2.8K shares- - Jul 31, 2025SAGE
Sage Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
21.5K shares- - Jul 31, 2025SAGE
Sage Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
19.2K shares- - Jun 11, 2025SAGE
Sage Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
21.5K shares- - Mar 31, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Sale(S)Direct10.9K shares at avg. $3.47$38K - Mar 6, 2025AMLX
Amylyx Pharmaceuticals, Inc.
Award(A)Direct68.4K shares- - Jan 3, 2025SAGE
Sage Therapeutics, Inc.
Award(A)DirectStock Options (Right to buy)
19.2K shares- - Sep 12, 2024AMLX
Amylyx Pharmaceuticals, Inc.
Purchase(P)Direct40K shares at avg. $2.53$101K - Aug 23, 2023AMLX
Amylyx Pharmaceuticals, Inc.
Exercise(M)Direct18.2K shares at avg. $6.88$125K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 10, 2026 |  AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 9,768 | $32.27 | $315,195 | Direct |
| Sep 10, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 1,042 | $33.23 | $34,626 | Direct |
| Aug 18, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 22,807 | - | $0 | Direct |
| Mar 5, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 95,990 | - | $0 | Direct |
| Mar 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 7,909 | $14.52 | $114,851 | Direct |
| Feb 2, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 3,557 | $14.65 | $52,097 | Direct |
| Jan 6, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 3,326 | $11.11 | $36,954 | Direct |
| Sep 30, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 10,558 | $14.65 | $154,650 | Direct |
| Jul 31, 2025 |  SAGE Sage Therapeutics, Inc. | Tender Offer(U) | 2,845 | - | - | Direct |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 21,500 | - | - | Direct |
| Jul 31, 2025 | SAGE Sage Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 19,154 | - | - | Direct |
| Jun 11, 2025 | SAGE Sage Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 21,500 | - | - | Direct |
| Mar 31, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Sale(S) | 10,896 | $3.47 | $37,806 | Direct |
| Mar 6, 2025 | AMLX Amylyx Pharmaceuticals, Inc. | Award(A) | 68,420 | - | - | Direct |
| Jan 3, 2025 | SAGE Sage Therapeutics, Inc. | Award(A) Stock Options (Right to buy) | 19,154 | - | - | Direct |
| Sep 12, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Purchase(P) | 40,000 | $2.53 | $101,368 | Direct |
| Aug 23, 2023 | AMLX Amylyx Pharmaceuticals, Inc. | Exercise(M) | 18,165 | $6.88 | $124,975 | Direct |
1-17 of 17 transactions
About FRATES JAMES M
FRATES JAMES M (SEC CIK 0001235598) files insider reports with the SEC as Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX) and Director of Sage Therapeutics, Inc. (SAGE).
Signal8 holds 14 ownership filings by FRATES JAMES M, all Form 4s, filed between Sep 5, 2024 and Sep 14, 2026. Those filings report 17 transactions, from Aug 23, 2023 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FRATES JAMES M's filings is in CAMBRIDGE, MA.
Recent filings by FRATES JAMES M
- Sep 10, 2026: Open-market sales of AMLX shares (2 lines, Form 4, code S).
- Aug 18, 2026: Grant or award of AMLX shares (Form 4, code A).
- Mar 5, 2026: Grant or award of AMLX shares (Form 4, code A).
- Mar 2, 2026: Open-market sale of AMLX shares (Form 4, code S).
- Feb 2, 2026: Open-market sale of AMLX shares (Form 4, code S).
Other insiders filing for Amylyx Pharmaceuticals, Inc. (AMLX)
- MILNE GEORGE M JR, Director
- Bedrosian Camille L, Chief Medical Officer
- Mazzariello Gina, Chief Legal Officer
- Klee Justin B., Co-Chief Executive Officer
- Cohen Joshua B, Co-Chief Executive Officer
- Firestone Karen, Director